- [18F]PI-2620 Phase 3 Histopathological StudyRecruitingNCT05641688Phase 3
Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.
- Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])RecruitingNCT07831824Phase 2/3
Sponsor listed in the registry: Lantheus Medical Imaging
- Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)RecruitingNCT07357519Phase 1/2
Sponsor listed in the registry: Lantheus Medical Imaging
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract CancerRecruitingNCT06298916Phase 1/2
Sponsor listed in the registry: Lantheus Medical Imaging
- PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate CancerCompletedNCT06074510Phase 4
Sponsor listed in the registry: Lantheus Medical Imaging
- Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy VolunteersCompletedNCT00750282Phase 2
Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.
- Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to HistopathologyCompletedNCT01020838Phase 3
Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.
- Test-retest Study With [18F]PI-2620 in PSP-RS and NDCCompletedNCT05187546Phase 1
Sponsor listed in the registry: Life Molecular Imaging GmbH · First submitted before Life Molecular Imaging GmbH became part of Lantheus Holdings, Inc.
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisCompletedNCT05184088Phase 3
Sponsor listed in the registry: Lantheus Germany GmbH · First submitted before Lantheus Germany GmbH became part of Lantheus Holdings, Inc.
- Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or InflammationCompletedNCT01103310Phase 1
Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.
- Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific ActivityCompletedNCT04715750Phase 1
Sponsor listed in the registry: Life Molecular Imaging GmbH · First submitted before Life Molecular Imaging GmbH became part of Lantheus Holdings, Inc.
- PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With InflammationsCompletedNCT01089998Phase 1
Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.
- Test-retest Study With [18F]FBB in Cardiac AmyloidosisCompletedNCT06790394Phase 1
Sponsor listed in the registry: Lantheus Germany GmbH · First submitted before Lantheus Germany GmbH became part of Lantheus Holdings, Inc.
- Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With ADCompletedNCT02681172Phase 4
Sponsor listed in the registry: Lantheus Biosciences Ltd. · First submitted before Lantheus Biosciences Ltd. became part of Lantheus Holdings, Inc.
- An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate CancerActive, not recruitingNCT05712473
Sponsor listed in the registry: Lantheus Medical Imaging
- Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCCWithdrawnNCT07084909Phase 2/3
Sponsor listed in the registry: Lantheus Medical Imaging
- I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).CompletedNCT03939689Phase 2
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Temporarily not availableNCT06033001
Sponsor listed in the registry: Lantheus Medical Imaging
- Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain InjuryTerminatedNCT05337774Phase 1
Sponsor listed in the registry: Life Molecular Imaging SA · First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc.
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerCompletedNCT02981368Phase 2/3
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerCompletedNCT03739684Phase 3
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary DiseaseCompletedNCT00162370Phase 4
Sponsor listed in the registry: Lantheus Medical Imaging
- DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYCompletedNCT03719612Phase 3
Sponsor listed in the registry: Lantheus Medical Imaging
- DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYCompletedNCT03571672Phase 3
Sponsor listed in the registry: Lantheus Medical Imaging
- A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery PressureCompletedNCT00918866Phase 4
Sponsor listed in the registry: Lantheus Medical Imaging
- A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical PracticeCompletedNCT00625365Phase 4
Sponsor listed in the registry: Lantheus Medical Imaging
- A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.CompletedNCT01347710Phase 3
Sponsor listed in the registry: Lantheus Medical Imaging
- A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart FailureCompletedNCT00891241Phase 1
Sponsor listed in the registry: Lantheus Medical Imaging
- Study of [3H] BMS747158 in Healthy Male SubjectsCompletedNCT00930631Phase 1
Sponsor listed in the registry: Lantheus Medical Imaging
- Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®CompletedNCT01299649
Sponsor listed in the registry: Lantheus Medical Imaging
- A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at StressCompletedNCT00707538Phase 1
Sponsor listed in the registry: Lantheus Medical Imaging
- A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158CompletedNCT00707499Phase 1
Sponsor listed in the registry: Lantheus Medical Imaging
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaStatus unknownNCT00874614Phase 2
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki DiseaseCompletedNCT00162032Phase 3
Sponsor listed in the registry: Lantheus Medical Imaging
- Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate CancerCompletedNCT02615067Phase 3
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaApproved for marketingNCT02961491
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk NeuroblastomaCompletedNCT00659984Phase 2
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)CompletedNCT01695044Phase 2
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- An Open-label Extension Study of PSMA ADC 2301 in mCRPCCompletedNCT02020135Phase 2
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerTerminatedNCT02483884Phase 1/2
Sponsor listed in the registry: Life Molecular Imaging SA · First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc.
- A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to HistopathologyCompletedNCT01667536Phase 2
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- PET Imaging of Intracranial Cancers With 18F-FSPGTerminatedNCT02370563Phase 1
Sponsor listed in the registry: Life Molecular Imaging SA · First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc.
- Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaCompletedNCT00458952Phase 1/2
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary SyndromeCompletedNCT00514501Phase 2
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Efficacy and Safety of Ultratrace™ Iobenguane I 131 in NeuroblastomaWithdrawnNCT00992173Phase 2
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid TumorsWithdrawnNCT00696930Phase 2
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- 99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404CompletedNCT01654874Phase 1
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node DissectionCompletedNCT01572701Phase 1
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate CancerCompletedNCT01615406Phase 1
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing ProstatectomyWithdrawnNCT01279785
Sponsor listed in the registry: Molecular Insight Pharmaceuticals, Inc. · First submitted before Molecular Insight Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.